Premium
Self ‐ Adjuvanting Synthetic Antitumor Vaccines from MUC1 Glycopeptides Conjugated to T ‐ Cell Epitopes from Tetanus Toxoid
Author(s) -
Cai Hui,
Chen MeiSha,
Sun ZhanYi,
Zhao YuFen,
Kunz Horst,
Li YanMei
Publication year - 2013
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201300390
Subject(s) - toxoid , glycopeptide , epitope , adjuvant , tetanus , cytotoxicity , immune system , muc1 , antibody , immunology , microbiology and biotechnology , vaccination , medicine , biology , antigen , in vitro , biochemistry , antibiotics
The T‐helper epitope peptide P30 (green in the scheme) from tetanus toxoid was used as the immunostimulant in MUC1 glycopeptide antitumor vaccines and apparently also acts as a built‐in adjuvant. P30‐conjugated glycopeptide vaccines containing three glycans in the immunodominant motifs PDTRP and GSTAP induced much stronger immune responses and complement dependent cytotoxicity mediated killing of tumor cells when applied in plain PBS solution without complete Freund's adjuvant.